SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: james who wrote (30)8/22/1998 11:11:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1073
 
James:

OSI started out as a Santa Cruz Biologicals-like business. It would not surprise me if they sold the reagents end to Calbiochem as they transitioned to therapeutics. I kissed them off as uninteresting when I looked at the protein project, TGFbeta-3. Then they started the phase I for the EGFR, and I perked up (I have some first-hand experience with EGFR, Proc Natl Acad Sci 91:7727-7731).

Then they pumped up Aston, and I really started to pay attention. Then they started to disclose some of the angiogenesis-related work, and I got more interested. Hoechst, the TKTX partner and licensee of tech from CEGE for epo, likes them for their small molecule efforts at tickling epo production...... I consider this as valuable effort on a learning curve, if nothing else. There's Her-2 and Hexokinase II. There's the Aurora license and stock. There's Anaderm and Helicon. To my knowledge, the Wyeth Ayerst license for diabetes is alive. Diagnostics with Bayer and Fujibiro.

The patent portfolio..... the screening patents.

Highly leveraged business plan. Company gets zero respect. Near-term danger??.... Pfizer could come up empty from the phase I. I say "who gives a damn, given the beating the stock has taken".

Cheers! Rick



To: james who wrote (30)8/22/1998 11:35:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1073
 
From what I can see, the priority date seems to be 7/18/89.....

5776502 : Methods of transcriptionally modulating gene expression

20 CLAIMS

What is claimed is:
1. A method for transcriptionally modulating the expression of a gene of interest in a multicellular organism which
comprises administering to said organism an amount of a molecule effective to modulate transcription of the gene of
interest,
wherein said gene of interest is operably linked to a nucleotide sequence regulating transcription of said gene,
which nucleotide sequence comprises a promoter and 5' nucleotide regulatory sequences of said gene,
wherein said molecule has a molecular weight of 2,000 daltons or leas, does not naturally occur in the organism,
and specifically modulates transcription of the gene of interest by:
1) binding directly to said nucleotide sequence regulating transcription, or
2) by binding directly to RNA produced by transcription from the gene of interest, or
3) by binding directly to a protein regulating transcription of said gene, with the proviso that said molecule
binds the protein at a site distinct from the normal ligand binding site if the protein is a receptor, and
wherein said binding of said molecule results in the transcriptional modulation of the expression of the gene of
interest within said organism.
2. A method of claim 1, wherein the molecule directly binds to said protein.
3. A method of claim 1, wherein the multicellular organism is a human being.
4. A method of claim 1, wherein the multicellular organism is an animal.
5. A method of claim 1, wherein the multicellular organism is a plant.
6. A method of claim 1, wherein the gene of interest is associated with modulation of the expression of the symptoms
of a disorder.
7. A method of claim 6, wherein the disorder is selected from the group consisting of cancer, hematopoetic
dysfunction, diabetes, tissue inflammation, atherosclerosis, viral infections, dysfunctions of memory or learning, and
dysfunctions in a cholesterol or other metabolic pathway.
8. A method of claim 4, wherein the gene of interest is a growth hormone gene and the organism is a cow, a pig, a
bird, a fish, a sheep, or a horse.
9. A method of claim 5, wherein the gene of interest is associated with an agronomically important trait.
10. A method of claim 1, wherein the administering comprises topical contact.
11. A method of claim 1, wherein the administering comprises oral, transdermal, intravenous, intramuscular or
subcutaneous administration.
12. A method of claim 1, wherein the gene of interest encodes a hematopoietic protein.
13. A method of claim 12, wherein the hematopoietic protein is a colony stimulating factor.
14. A method of claim 13, wherein the colony stimulating factor is GM-CSF, G-CSF, M-CSF or EPO.
15. A method of claim 1, wherein the gene of interest encodes an interleukin.
16. A method of claim 15, wherein the interleukin is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7 or IL-8.
17. A method of claim 1, wherein the gene of interest encodes a growth hormone.
18. A method of claim 17, wherein the growth hormone is human, bovine, porcine, avian, ovine, piscine or equine
growth hormone.
19. A method of claim 1, wherein the gene of interest encodes an oncogene.
20. A method of claim 19, wherein the oncogene is phl-abl, H-ras, N-ras, K-ras, neu, or src.



To: james who wrote (30)8/23/1998 12:47:00 AM
From: scaram(o)uche  Read Replies (2) | Respond to of 1073
 
James:

I would suggest a cruise of the recent 10-Q and 10-K. This will give you a concept of the quality of the research capacities behind the new Vanderbilt/diabetes agreement, for which a corporate partner is being sought (search term is Granner DK)....

Yamada K, et al. [See Related Articles]
Efficient large-scale transformation of yeast.
Biotechniques. 1998 Apr; 24(4): 596-598. No abstract available.
PMID: 9564532; UI: 98225719.

Scott DK, et al. [See Related Articles]
Further characterization of the glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. The role of
the glucocorticoid receptor-binding sites.
Mol Endocrinol. 1998 Apr; 12(4): 482-491.
PMID: 9544984; UI: 98204545.

Sutherland C, et al. [See Related Articles]
Activation of the ras mitogen-activated protein kinase-ribosomal protein kinase pathway is not required for the
repression of phosphoenolpyruvate carboxykinase gene transcription by insulin.
J Biol Chem. 1998 Feb 6; 273(6): 3198-3204.
PMID: 9452431; UI: 98123082.

Koval JA, et al. [See Related Articles]
Regulation of hexokinase II activity and expression in human muscle by moderate exercise.
Am J Physiol. 1998 Feb; 274(2 Pt 1): E304-E308.
PMID: 9486162; UI: 98147116.

O'Doherty RM, et al. [See Related Articles]
Analysis of insulin-stimulated skeletal muscle glucose uptake in conscious rat using isotopic glucose analogs.
Am J Physiol. 1998 Feb; 274(2 Pt 1): E287-E296.
PMID: 9486160; UI: 98147114.

Printz RL, et al. [See Related Articles]
Hexokinase II gene: structure, regulation and promoter organization.
Biochem Soc Trans. 1997 Feb; 25(1): 107-112. Review. No abstract available.
PMID: 9056853; UI: 97209678.

Sutherland C, et al. [See Related Articles]
Oxidative and chemical stress mimic insulin by selectively inhibiting the expression of phosphoenolpyruvate
carboxykinase in hepatoma cells.
Diabetes. 1997 Jan; 46(1): 17-22.
PMID: 8971075; UI: 97126151.

Scott DK, et al. [See Related Articles]
The orphan receptor COUP-TF binds to a third glucocorticoid accessory factor element within the
phosphoenolpyruvate carboxykinase gene promoter.
J Biol Chem. 1996 Dec 13; 271(50): 31909-31914.
PMID: 8943235; UI: 97112982.

O'Brien RM, et al. [See Related Articles]
Regulation of gene expression by insulin.
Physiol Rev. 1996 Oct; 76(4): 1109-1161. Review.
PMID: 8874496; UI: 97028483.

O'Doherty RM, et al. [See Related Articles]
Transcription of the rat skeletal muscle hexokinase II gene is increased by acute exercise.
J Appl Physiol. 1996 Aug; 81(2): 789-793.
PMID: 8872647; UI: 97026469.

Osawa H, et al. [See Related Articles]
Identification and characterization of basal and cyclic AMP response elements in the promoter of the rat hexokinase II
gene.
J Biol Chem. 1996 Jul 19; 271(29): 17296-17303.
PMID: 8663388; UI: 96291882.

Osawa H, et al. [See Related Articles]
Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin.
J Biol Chem. 1996 Jul 12; 271(28): 16690-16694.
PMID: 8663315; UI: 96279242.

Wang JC, et al. [See Related Articles]
Hepatic nuclear factor 3 is an accessory factor required for the stimulation of phosphoenolpyruvate carboxykinase gene
transcription by glucocorticoids.
Mol Endocrinol. 1996 Jul; 10(7): 794-800.
PMID: 8813720; UI: 96408713.

Chang PY, et al. [See Related Articles]
Overexpression of hexokinase II in transgenic mice. Evidence that increased phosphorylation augments muscle glucose
uptake.
J Biol Chem. 1996 Jun 21; 271(25): 14834-14839.
PMID: 8662926; UI: 96278971.

Ardehali H, et al. [See Related Articles]
A novel (TA)n polymorphism in the hexokinase II gene: application to noninsulin-dependent diabetes mellitus in the Pima
Indians.
Hum Genet. 1996 Apr; 97(4): 482-485.
PMID: 8834247; UI: 96431165.

Scott DK, et al. [See Related Articles]
Identification and charaterization of the second retinoic acid response element in the phosphoenolpyruvate carboxykinase
gene promoter.
J Biol Chem. 1996 Mar 15; 271(11): 6260-6264.
PMID: 8626419; UI: 96198086.

Taylor RW, et al. [See Related Articles]
Variant sequences of the Hexokinase II gene in familial NIDDM.
Diabetologia. 1996 Mar; 39(3): 322-328.
PMID: 8721778; UI: 96361932.

Sutherland C, et al. [See Related Articles]
New connections in the regulation of PEPCK gene expression by insulin.
Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29; 351(1336): 191-199. Review.
PMID: 8650266; UI: 96244093.

Parsa R, et al. [See Related Articles]
Induction of the glucokinase gene by insulin in cultured neonatal rat hepatocytes. Relationship with DNase-I
hypersensitive sites and functional analysis of a putative insulin-response element.
Eur J Biochem. 1996 Feb 15; 236(1): 214-221.
PMID: 8617267; UI: 96184900.

Ludwig DS, et al. [See Related Articles]
Examination of the phosphoenolpyruvate carboxykinase gene promoter in patients with noninsulin-dependent diabetes
mellitus.
J Clin Endocrinol Metab. 1996 Feb; 81(2): 503-506.
PMID: 8636258; UI: 96225510.

(snip)